Abstract
Immune checkpoint inhibitors (ICIs) have shown clinical efficacy when administered in combination with neoadjuvant chemotherapy (NACT) for the treatment of triple negative breast cancer (TNBC). However, suitable complementary diagnostics to help guide and tailor treatment recommendations are still lacking. Ki67 is a well accepted and routinely used marker that tracks proliferation and has been shown to predict efficacy of neoadjuvant chemotherapy. Forkhead Box C1 (FOXC1), a transcriptional driver of cell plasticity/partial EMT/metastasis/immune evasion has proven prognostic value, but remains of uncertain predictive value.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
